• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

作者信息

Hoetelmans R M, Reijers M H, Weverling G J, ten Kate R W, Wit F W, Mulder J W, Weigel H M, Frissen P H, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen J H, Lange J M

机构信息

Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.

出版信息

AIDS. 1998 Jul 30;12(11):F111-5. doi: 10.1097/00002030-199811000-00002.

DOI:10.1097/00002030-199811000-00002
PMID:9708400
Abstract

OBJECTIVE

To investigate the relationship between exposure to antiretroviral drugs and the initial decline of plasma HIV-1 RNA.

DESIGN

Open-label study in antiretroviral-naive HIV-1 infected patients using a quadruple drug regimen [nelfinavir (NFV), saquinavir (SQV), stavudine, and lamivudine].

METHODS

The elimination rate constant (k) for HIV-1 clearance was calculated during the first 2 weeks of treatment in 29 patients. Exposure to NFV and SQV was quantified on each study visit. Observed NFV and SQV concentrations were related to those expected in a reference population and a concentration ratio was calculated. The median concentration ratios for NFV and SQV, the baseline CD4+ lymphocyte count and baseline log10 HIV-1 RNA were correlated with k.

RESULTS

A significant positive correlation was observed between k and the median NFV (P = 0.001) or SQV concentration ratio (P = 0.016) in univariate analysis. In multivariate analyses, the median NFV concentration ratio remained significantly correlated with k.

CONCLUSIONS

The variation in the rate of decline of plasma HIV-1 RNA between patients after the initiation of a quadruple drug regimen could be explained by differences in exposure to NFV or SQV. Determination of k could be used to optimise further antiretroviral drug therapy and may be a first tool to assess antiretroviral activities of new or increasing doses of drugs administered in combination regimens. Furthermore, our data suggest that exposure to antiretroviral drugs should be incorporated in mathematical models to describe HIV-1 dynamics in more detail.

摘要

相似文献

1
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
AIDS. 1998 Jul 30;12(11):F111-5. doi: 10.1097/00002030-199811000-00002.
2
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.
J Acquir Immune Defic Syndr. 2000 Feb 1;23(2):128-37. doi: 10.1097/00126334-200002010-00004.
3
Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.使用利托那韦/沙奎那韦或利托那韦/沙奎那韦/司他夫定治疗期间的脑脊液HIV-1 RNA
AIDS. 2000 Jul 28;14(11):1583-9. doi: 10.1097/00002030-200007280-00014.
4
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.司他夫定、奈韦拉平、奈非那韦和沙奎那韦联合用药作为利托那韦或茚地那韦治疗失败后的挽救方案的疗效、耐受性和药代动力学。
AIDS Res Hum Retroviruses. 2001 Jan 20;17(2):93-8. doi: 10.1089/08892220150217175.
5
Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.奈非那韦联合沙奎那韦作为挽救疗法用于对标准三联疗法耐药的HIV感染患者的病毒学疗效及血浆药物浓度
Eur J Med Res. 1999 Feb 25;4(2):54-8.
6
Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).基于奈非那韦方案的病毒学反应:药代动力学与耐药性突变(VIRAPHAR研究)
AIDS. 2002 Jul 5;16(10):1331-40. doi: 10.1097/00002030-200207050-00004.
7
Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.每日两次服用沙奎那韦软胶囊(SGC),联合或不联合奈非那韦,以及每日三次服用沙奎那韦-SGC,用于HIV感染三联联合治疗的长期疗效和安全性:100周随访
Antivir Ther. 2003 Feb;8(1):37-42.
8
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).比较沙奎那韦软胶囊与茚地那韦作为三联疗法一部分的随机试验(CHEESE研究)。
AIDS. 1999 May 7;13(7):F53-8. doi: 10.1097/00002030-199905070-00001.
9
Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.在患者单独使用沙奎那韦或与利托那韦或奈非那韦联合进行蛋白酶抑制剂治疗期间,对沙奎那韦进行治疗药物监测。
Eur J Med Res. 2000 Feb 28;5(2):59-62.
10
Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.
AIDS. 1998 Jul 30;12(11):F103-9. doi: 10.1097/00002030-199811000-00001.

引用本文的文献

1
Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.在基于依非韦伦的治疗方案中,合并结核分枝杆菌感染与未合并结核分枝杆菌感染的 HIV 感染者的病毒衰减率相似。
Clin Infect Dis. 2011 Feb 15;52(4):547-50. doi: 10.1093/cid/ciq196. Epub 2011 Jan 20.
2
The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.A5146的设计与实施,这是一项前瞻性试验,旨在评估在有抗逆转录病毒治疗经验的HIV感染患者中使用抑制商数进行治疗药物监测的效用。
HIV Clin Trials. 2008 Jan-Feb;9(1):61-72. doi: 10.1310/hct0901-61.
3
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
CYP2C19基因多态性对HIV患者中奈非那韦向M8生物转化的影响。
Br J Clin Pharmacol. 2008 Apr;65(4):548-57. doi: 10.1111/j.1365-2125.2007.03039.x. Epub 2007 Oct 8.
4
Nelfinavir: a review of its use in the management of HIV infection.奈非那韦:关于其在HIV感染管理中应用的综述
Drugs. 2005;65(15):2209-44. doi: 10.2165/00003495-200565150-00015.
5
Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.
Curr HIV/AIDS Rep. 2004 Apr;1(1):33-9. doi: 10.1007/s11904-004-0005-z.
6
Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.群体药代动力学在抗逆转录病毒药物治疗评估中的应用及影响
Clin Pharmacokinet. 2005;44(6):591-625. doi: 10.2165/00003088-200544060-00003.
7
Practical guidelines to interpret plasma concentrations of antiretroviral drugs.解读抗逆转录病毒药物血浆浓度的实用指南。
Clin Pharmacokinet. 2004;43(13):845-53. doi: 10.2165/00003088-200443130-00002.
8
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.在未经过挑选的HIV-1感染人群中,奈韦拉平血浆浓度低预示着病毒学治疗失败。
Clin Pharmacokinet. 2003;42(6):599-605. doi: 10.2165/00003088-200342060-00009.
9
Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?治疗药物监测:有助于优化对抗逆转录病毒药物的反应?
Drugs. 2003;63(8):741-53. doi: 10.2165/00003495-200363080-00002.
10
Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?人类免疫缺陷病毒/获得性免疫缺陷综合征中的治疗药物监测。何去何从?
Arch Pathol Lab Med. 2003 Jan;127(1):102-5. doi: 10.5858/2003-127-102-TDMIHI.